^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    miR-1293 expression

    i
    Other names: miR-1293, MicroRNA 1293, Hsa-Mir-1293, Hsa-MiR-1293, MIR1293, MIMAT0005883, MI0006355, MIRN1293, Mir-1293
    Entrez ID:
    100302220
    3d
    The circRNA circSCAF8 promotes tumor growth and metastasis of gastric cancer via miR-1293/TIMP1signaling. (PubMed, Gene Ther)
    Subsequent rescue experiments revealed that TIMP1 overexpression reversed the impact of circSCAF8 shRNA viruses on gastric cancer. In conclusion, circSCAF8 expression was elevated in gastric cancer, and circSCAF8 shRNA viruses inhibited gastric cancer growth and metastasis by upregulating TIMP1 expression via miR-1293.
    Journal
    |
    TIMP1 (Tissue inhibitor of metalloproteinases 1) • MIR1293 (MicroRNA 1293)
    |
    TIMP1 overexpression • KIM1 expression • TIMP1 expression • miR-1293 expression
    9ms
    miR-1293 suppresses osteosarcoma progression by modulating drug sensitivity in response to cisplatin treatment. (PubMed, Int Immunopharmacol)
    Furthermore, miR-1293 inhibits osteosarcoma progression by targeting TIMP1 to inactivate the Notch1/Hes1 and TGFBR1/Smad2/3 pathways, thereby promoting tumour cell death. The findings presented herein unveil a novel mechanism for enhancing cisplatin sensitivity and proposed a potential therapeutic strategy for osteosarcoma through pre-chemotherapy supplementation of miR-1293.
    Journal
    |
    NOTCH1 (Notch 1) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • HES1 (Hes Family BHLH Transcription Factor 1) • MIR1293 (MicroRNA 1293) • TFAP2A (Transcription Factor AP-2 Alpha) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    |
    miR-1293 expression
    |
    cisplatin
    3years
    miR-1293 acts as a tumor promotor in lung adenocarcinoma via targeting phosphoglucomutase 5. (PubMed, PeerJ)
    Administration of miR-1293 antagomir reduced tumor volume and staining of Ki-67 and MMP9, but elevated PGM5 expression in vivo. miR-1293 promoted the proliferation, migration and invasion of LUAD cells via targeting PGM5, which indicated that miR-1293 might serve as a potential therapeutic target for LUAD patients.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • MIR1293 (MicroRNA 1293)
    |
    miR-1293 expression • MMP9 elevation